Cetera Investment Advisers Increases Position in Lantheus Holdings, Inc. (NASDAQ:LNTH)

Cetera Investment Advisers boosted its holdings in shares of Lantheus Holdings, Inc. (NASDAQ:LNTH - Free Report) by 22.7% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 23,358 shares of the medical equipment provider's stock after acquiring an additional 4,320 shares during the period. Cetera Investment Advisers' holdings in Lantheus were worth $2,090,000 at the end of the most recent reporting period.

Several other large investors also recently bought and sold shares of LNTH. Kestra Investment Management LLC acquired a new position in shares of Lantheus in the 4th quarter worth approximately $27,000. Summit Securities Group LLC acquired a new position in shares of Lantheus in the 4th quarter worth approximately $37,000. UMB Bank n.a. lifted its holdings in shares of Lantheus by 31.5% in the 4th quarter. UMB Bank n.a. now owns 559 shares of the medical equipment provider's stock worth $50,000 after acquiring an additional 134 shares during the last quarter. Parkside Financial Bank & Trust lifted its holdings in shares of Lantheus by 49.4% in the 4th quarter. Parkside Financial Bank & Trust now owns 847 shares of the medical equipment provider's stock worth $76,000 after acquiring an additional 280 shares during the last quarter. Finally, 1620 Investment Advisors Inc. acquired a new position in shares of Lantheus in the 4th quarter worth approximately $125,000. Hedge funds and other institutional investors own 99.06% of the company's stock.

Insider Activity at Lantheus

In related news, CFO Robert J. Jr. Marshall sold 10,000 shares of the stock in a transaction on Monday, March 17th. The shares were sold at an average price of $100.52, for a total transaction of $1,005,200.00. Following the completion of the sale, the chief financial officer now owns 113,860 shares in the company, valued at $11,445,207.20. This represents a 8.07% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Mary Anne Heino sold 53,107 shares of the stock in a transaction on Monday, March 3rd. The stock was sold at an average price of $94.35, for a total transaction of $5,010,645.45. Following the sale, the director now owns 440,399 shares of the company's stock, valued at approximately $41,551,645.65. This represents a 10.76% decrease in their position. The disclosure for this sale can be found here. Insiders have sold 63,109 shares of company stock valued at $6,016,046 in the last ninety days. Insiders own 1.50% of the company's stock.

Analyst Upgrades and Downgrades

LNTH has been the topic of several recent research reports. B. Riley cut their target price on shares of Lantheus from $127.00 to $122.00 and set a "buy" rating on the stock in a research note on Friday, March 21st. Wall Street Zen raised shares of Lantheus from a "hold" rating to a "buy" rating in a research note on Thursday, May 8th. Finally, Truist Financial cut their target price on shares of Lantheus from $127.00 to $117.00 and set a "buy" rating on the stock in a research note on Thursday, May 8th. Seven equities research analysts have rated the stock with a buy rating, According to data from MarketBeat, the company currently has a consensus rating of "Buy" and an average price target of $132.67.

Lantheus Stock Performance

Shares of NASDAQ:LNTH traded down $0.89 during trading hours on Friday, reaching $73.86. The stock had a trading volume of 671,503 shares, compared to its average volume of 988,498. Lantheus Holdings, Inc. has a 1 year low of $73.11 and a 1 year high of $126.89. The firm's 50 day moving average is $94.56 and its 200-day moving average is $92.08. The stock has a market capitalization of $5.11 billion, a price-to-earnings ratio of 12.29 and a beta of 0.23.

Lantheus (NASDAQ:LNTH - Get Free Report) last posted its earnings results on Wednesday, May 7th. The medical equipment provider reported $1.53 EPS for the quarter, missing analysts' consensus estimates of $1.64 by ($0.11). The company had revenue of $372.76 million during the quarter, compared to analysts' expectations of $377.37 million. Lantheus had a net margin of 28.57% and a return on equity of 44.29%. The company's quarterly revenue was up .8% on a year-over-year basis. During the same period last year, the business earned $1.69 earnings per share. Analysts forecast that Lantheus Holdings, Inc. will post 6.01 EPS for the current year.

Lantheus Profile

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.